Administration of the BET inhibitor selectively displaces BRD4 from these super-enhancer domains, resulting in downregulation of key oncogene expression, induction of leukemic differentiation, and apoptosis in AML cells. This evidence concerns the gene BRD4 and acute myeloid leukemia.